| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3695 |
| Trial ID | NCT06180174 |
| Disease | B Cell Lymphoma | Non-Hodgkin's Lymphoma |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | MC-1-50 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase I Clinical Study of CD19-targeting Chimeric Antigen Receptor T Lymphocyte (MC-1-50) Formulation for the Treatment of Relapsed/Refractory CD19-positive B-cell Non-Hodgkin Lymphoma (B-NHL) |
| Year | 2023 |
| Country | China |
| Company sponsor | Chongqing Precision Biotech Co., Ltd |
| Other ID(s) | PB10 |
| Cohort 1 | |||||||||||
|
|||||||||||